Zimbabwe rolls out Lenacapavir for HIV treatment

Zimbabwe rolls out Lenacapavir; Science confirms HIV capsid is a strong drug target despite resistance

Source : Down To Earth

Relevance (UPSC)
Health, Social sector; Role of international organisations (WHO, UNAIDS, Global Fund)

Important Keywords for Prelims and Mains

For Prelims:

Lenacapavir, PrEP, PEP, ART, HIV capsid, Reverse transcriptase, Protease, Integrase, FDA (June 18, 2025), WHO early access, Global Fund, UNAIDS 95-95-95, Combination prevention

For Mains:

Long-acting injectables, Adherence & stigma, Combination prevention strategy, Structural biology drug targets, Resistance “fitness cost”, Sub-Saharan Africa HIV burden, 2030 AIDS-free target

Why in News?

Zimbabwe began rolling out Lenacapavir, the first twice-yearly injectable PrEP for HIV, making it an early adopter globally (launch on Feb 19, 2026).
A new study shows that to escape lenacapavir, HIV must mutate the capsid in ways that damage its own fitness, reaffirming capsid as a strong drug target.

Background

HIV drug history shows monotherapy fails due to rapid mutation and resistance.
1987 (4 years after HIV identified as the cause of AIDS): zidovudine (AZT) targeted reverse transcriptase, but HIV quickly evolved resistance due to copying “mistakes” during RNA→DNA conversion.
This led to combination antiretroviral therapy targeting multiple viral proteins (reverse transcriptase, protease, integrase) — focusing on viral regions that are “must keep” for survival.

What is Lenacapavir?

What it is

First twice-yearly injectable PrEP: two doses per year for HIV prevention.
A long-acting alternative to daily pills, useful for people facing:
- adherence difficulties
- stigma
- limited access to healthcare
Developed by scientists at Gilead Sciences.

How it works as a long-acting drug (science detail)

FDA approved (June 18, 2025) the world’s first capsid-based HIV inhibitor.
Injected under the skin of the abdomen once every six months, forming a slow-release reservoir that steadily releases drug into bloodstream.
In trials, it showed 100% effectiveness in preventing HIV infection in high-risk individuals (not a cure; described as “next best thing to a vaccine” in popular science coverage).

What it is NOT

Not a vaccine
Not for HIV-positive persons (PrEP is strictly for those who test HIV-negative)
Does not replace: condoms, oral PrEP, other injectables, abstinence, faithfulness, etc.
Does not replace ART for people living with HIV

Zimbabwe Rollout:

Where & when

Rollout began Feb 19, 2026 in Epworth, a shanty settlement ~20 km south of Harare.

Scale

Started with 46,000 doses.
Targets 46,000+ high-risk people across 24 sites nationwide.

Funding

Funded by the U.S. government and the Global Fund.

WHO early access

Zimbabwe is among nine countries selected by WHO for early receipt of this next-generation prevention injection.

Priority groups

Adolescent girls and young women
Sex workers
Homosexual communities
Pregnant and breastfeeding women
Others facing high social/economic vulnerability

Combination Prevention Strategy (Zimbabwe’s model)

Zimbabwe emphasised lenacapavir complements, not replaces, existing tools.

Principle

No “magic bullet” can end HIV. A combination of proven interventions is needed.

Behavioural interventions (explicit list)

Abstinence
Monogamy / being faithful
Reducing concurrent sexual partnerships

Biomedical interventions (explicit list)

HIV testing and counselling
Treatment (ART)
Proper and consistent condom use
Management of STIs
PEP
PrEP

Zimbabwe’s PrEP toolkit (WHO-recommended options adopted)

Oral PrEP (2016)
Dapivirine vaginal ring (2021)
Long-acting injectable cabotegravir (2024)
Lenacapavir (2026)
Zimbabwe notes it has progressively adopted all four WHO-recommended PrEP options.

Community messaging & misconception risk

Bernard Madzima (National AIDS Council CEO): important for young women, who may lack power to negotiate condom use.
Rev. Maxwell Kapachawo (activist pastor, openly HIV+ since 2005): warned misconceptions could make some people on ART wrongly default, thinking lenacapavir replaces daily treatment.

HIV Science Link: Why the Capsid Target Matters (Despite Resistance)

Why capsid became a target

1999 Science paper explained capsid folding into a unique protective 3D shape.
Later, most capsid mutations were found to make HIV non-infectious → capsid is essential and fragile.

Resistance finding

In treatment settings, resistance mutations appeared mainly when lenacapavir was effectively acting alone (without other fully active drugs).
In proper combination therapy, suppression largely held.
Lab-engineered resistant viruses often replicated at only 20–30% of normal levels even without drug → escaping lenacapavir damages the capsid and weakens HIV.

Implication

Capsid is a high-constraint target: HIV cannot afford to change it too much.
Opens door to:
- new capsid-focused drugs
- exploring protective shells of other viruses as drug targets
Also highlights: breakthroughs often come from persistence, not sudden inspiration (solubility issue turned into long-acting advantage).

Broader Sub-Saharan Context

HIV/AIDS has killed 44+ million since early 1980s.
Of ~41 million people living with HIV globally, ~27 million are in Sub-Saharan Africa (~67%), despite the region having ~12% of global population.
Global new infections declined 33%+ since 2005, but the region still faces:
- ~700,000 new infections annually
- ~300,000 AIDS-related deaths annually
Young women (15–24) bear disproportionate burden.

Significance

Adherence revolution: Two injections/year reduces pill fatigue and missed doses.
Stigma reduction: More private than daily pills.
Choice-based prevention: Expands PrEP options within combination prevention.
Targets high-risk groups effectively: especially adolescent girls/young women.
Science reassurance: capsid targeting remains strong because resistance weakens HIV.
2030 goal support: strengthens path to ending AIDS as public health threat.

Challenges/Concerns

Misconceptions: PrEP vs ART confusion may cause ART default (needs communication).
Testing requirement: PrEP must be given only to HIV-negative persons → strong screening + follow-up essential.
Funding sustainability: reliance on external support (U.S. + Global Fund).
Delivery capacity: scale-up beyond 24 sites, supply chain, trained workforce.
Resistance risk in treatment misuse: “acting solo” lesson underscores need for correct regimens.

Conclusion

Zimbabwe’s early roll-out of lenacapavir shows how long-acting prevention can align with real-life barriers like adherence and stigma. Simultaneously, scientific evidence confirms that the HIV capsid is an excellent drug target: even when resistance emerges, it comes at a heavy cost to the virus. Together, these developments strengthen the case for long-acting, capsid-targeted strategies within a combination prevention framework to accelerate progress toward an AIDS-free future.

UPSC PYQ

Q. Which of the following diseases can be transmitted from one person to another through tattooing?

Chikungunya
Hepatitis B
HIV-AIDS

Select the correct answer using the codes given below:

1. 1 only
2. 2 and 3 only
3. 1 and 3 only
4. 1, 2 and 3

Answer: B Explanation Statement 1: Chikungunya Incorrect

Chikungunya is caused by a virus transmitted primarily by Aedes mosquitoes.
It is not a blood-borne infection transmitted through contaminated needles.
There is no standard evidence that it spreads through tattooing.

Statement 2: Hepatitis B Correct

Hepatitis B is a blood-borne viral infection (HBV).
It can spread through:
- Contaminated needles
- Blood-to-blood contact
Tattooing involves repeated skin piercing, creating a pathway for infected blood if equipment is not sterilised.
HBV has a high transmission rate via needle exposure.

Statement 3: HIV-AIDS Correct

HIV is also a blood-borne virus.
It spreads through:
- Infected blood
- Contaminated needles
Unsafe tattooing practices can transmit HIV if sterilisation is inadequate.

CARE MCQ

Q. With reference to Lenacapavir and HIV prevention, consider the following statements:

Lenacapavir is the first twice-yearly injectable PrEP for HIV prevention.
PrEP is meant for people living with HIV as a substitute for ART.
Zimbabwe’s rollout began in Epworth, about 20 km south of Harare, with 46,000 doses across 24 sites.
Resistance to lenacapavir can occur, but strong resistance mutations can reduce viral replication to about 20–30% of normal levels.

Which of the statements given above is/are correct?